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Introduction. Despite the existing evidence that methotrexate-associated liver toxicity is 
related to comorbid risk factors and common NSAIDS and steroid therapy use rather than to 
methotrexate itself, significant research continues in the monitoring of low-dose methotrexate 
in patients with JIA. The gold standard investigation remains to be liver biopsy with its 
potential medical risks. However, a number of new evaluation techniques have been developed 
for this purpose, including transient liver elastography. Moreover, MTHFR genetic 
susceptibility according to Genome-Wide Association Studies (GWAS) is being involved in 
most treatment regimen toxicities.  
Aim of the study. To appreciate the importance of MTHFR genetic polymorphism and liver 
elastography screening in children with JIA prior to use of low-dose methotrexate treatment.  
Materials and methods. There has been initiated an observational case-control study, 
involving at least 24 patients using low-dose methotrexate for JIA treatment. All children 
underwent transient unidimensional liver elastography scanning for estimation of liver toxicity 
according to EFSUMB pediatric reference values. The statistical evaluation was done through 
IBM SPSS 22 Software.   
Results. The study sample included 40 children aged between 2 and 18 years. There has been 
determined 6 (15%) cases of combined 677C/T and 1298A/C heterozygote significant 
mutation, 6 (15%) cases of 677T/T significant homozygotes and 28 (70%) cases of non-
significant MTHFR polymorphisms. Children without significant MTHFR polymorphisms had 
a 67,8% rate of increased liver stiffness and a moderate to low disease activity in the first 148,8 
weeks of low-dose methotrexate use (95% CI 2.0-4.2, p=0,00012). In the significant mutation 
groups, a 41,6% cases resulted in normal liver stiffness values after 6 months of low-dose 
methotrexate monotherapy use as well as low response with high disease activity according to 
DAS28 (95% CI 3,6-6.1, p=0,00026).  
Conclusions. The value of MTHFR genetic screening and liver stiffness evaluation is well 
proved in children with low-dose methotrexate JIA treatment. The significant mutations could 
lead to 4-fold risk of high disease activity and normal liver stiffness despite the appropriate 
treatment regimen.   
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Introduction. Seizures in children are the most common neurological manifestations. 0,5-1%  
of children in the USA and Europe have occasional seizures, caused by metabolic or 
